265 related articles for article (PubMed ID: 2698902)
1. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
Tsouderos Y
Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
[TBL] [Abstract][Full Text] [Related]
2. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg.
Tsouderos Y
Z Kardiol; 1991; 80 Suppl 7():95-101. PubMed ID: 1792820
[TBL] [Abstract][Full Text] [Related]
3. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
Geroulakos G; Nicolaides AN
Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
Duchene Marullaz P; Amiel M; Barbe R
Int Angiol; 1988; 7(2 Suppl):25-32. PubMed ID: 3053940
[TBL] [Abstract][Full Text] [Related]
5. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
Amato C
Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
[TBL] [Abstract][Full Text] [Related]
6. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
Cospite M; Dominici A
Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
Laurent R; Gilly R; Frileux C
Int Angiol; 1988; 7(2 Suppl):39-43. PubMed ID: 3053942
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"].
Carpentier PH; Mathieu M
J Mal Vasc; 1998 Apr; 23(2):106-12. PubMed ID: 9608923
[TBL] [Abstract][Full Text] [Related]
9. [A double-blind study comparing the clinical efficacy of the preparation F-117 (hidrosmin) versus diosmin in the treatment of patients with peripheral venous disorders].
Honorato Pérez J; Arcas Meca R
Rev Med Univ Navarra; 1990; 34(2):77-9. PubMed ID: 2130425
[TBL] [Abstract][Full Text] [Related]
10. [Study of the pharmacodynamic activity of daflon 500 mg].
Amiel M; Barbe R
Ann Cardiol Angeiol (Paris); 1998 Mar; 47(3):185-8. PubMed ID: 9772947
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
Cappelli R; Pecchi S; Oberhauser V; Forconi S; Di Perri T
Int J Clin Pharmacol Res; 1987; 7(4):291-9. PubMed ID: 3596872
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of mesoglycan in patients with previous deep venous thrombosis and chronic venous insufficiency.
Andreozzi GM
Minerva Cardioangiol; 2007 Dec; 55(6):741-53. PubMed ID: 18091643
[TBL] [Abstract][Full Text] [Related]
13. [Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone].
Weindorf N; Schultz-Ehrenburg U
Z Hautkr; 1987 Jan; 62(1):28-38. PubMed ID: 3554800
[TBL] [Abstract][Full Text] [Related]
14. Daflon 500 mg: symptoms and edema clinical update.
Ramelet AA
Angiology; 2005; 56 Suppl 1():S25-32. PubMed ID: 16193223
[TBL] [Abstract][Full Text] [Related]
15. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
Struckmann JR; Nicolaides AN
Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
[TBL] [Abstract][Full Text] [Related]
16. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
Godeberge P
Angiology; 1994 Jun; 45(6 Pt 2):574-8. PubMed ID: 8203790
[TBL] [Abstract][Full Text] [Related]
17. From symptoms to leg edema: efficacy of Daflon 500 mg.
Nicolaides AN
Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
[TBL] [Abstract][Full Text] [Related]
18. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy.
Ting AC; Cheng SW; Wu LL; Cheung GC
Vasc Surg; 2001; 35(6):443-7. PubMed ID: 16222383
[TBL] [Abstract][Full Text] [Related]
19. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
Lyseng-Williamson KA; Perry CM
Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency.
Roztocil K; Stvrtinová V; Strejcek J
Int Angiol; 2003 Mar; 22(1):24-31. PubMed ID: 12771852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
